[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital of Chongqing Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":577},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,41,60,89,112,135,157,177,196,216,237,269,287,311,335,361,384,407,428,443,466,487,509,534,557],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100608560","phase-2-selenium-supplementation-for-improving-depression-in-children-and-adolescents-efficacy-and-mechanistic-study-100608560",false,"NCT07203144","Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study","Inclusion Criteria:\n\n* Aged 12-18 years;\n* Diagnosed with major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), using the K-SADS-PL diagnostic tool;\n* A score of ≥40 on the Children's Depression Rating Scale-Revised (CDRS-R);\n* Adequate visual and auditory abilities to complete the study;\n* Willingness to participate in the study with informed consent signed by both the participant and a legal guardian.\n\nExclusion Criteria:\n\n* Patients with severe psychiatric disorders such as bipolar disorder, schizophrenia, bulimia nervosa, anorexia nervosa, or primary obsessive-compulsive disorder;\n* Those with severe physical illnesses or other life-threatening conditions; patients in a current depressive episode with a clear suicidal plan or history of suicide attempt;\n* Individuals with a history of substance or drug abuse;\n* Those requiring immediate hospitalization for psychiatric disorders;\n* Patients currently taking medications contraindicated with the investigational drug or that may interfere with its efficacy;\n* Those who have received modified electroconvulsive therapy (MECT) within the past 12 months;\n* Individuals allergic to selenium yeast protein, including those with allergic rhinitis, gastrointestinal sensitivity, allergic constitution, or autoimmune diseases such as Graves' disease or Hashimoto's thyroiditis;\n* Patients with contraindications to magnetic resonance imaging (MRI);\n* Left-handed individuals.","ALL","12 Years","18 Years",{"count":20,"type":21},172,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.",[27],"Depression - Major Depressive Disorder","RECRUITING","2026-08-13",{"date":31,"type":32},"2026-08-17","ACTUAL",{"date":34,"type":32},"2025-12-31",{"date":36,"type":21},"2027-04-01",{"name":38,"class":39},"First Affiliated Hospital of Chongqing Medical University","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":40},"100607199","efficacy-and-safety-of-transcranial-alternating-current-stimulation-tacs-combined-with-stable-medication-in-adolescents-with-depression-a-randomized-double-blind-controlled-pilot-study-100607199","NCT07185451","Efficacy and Safety of Transcranial Alternating Current Stimulation (tACS) Combined With Stable Medication in Adolescents With Depression","Efficacy and Safety of Transcranial Alternating Current Stimulation (tACS) Combined With Stable Medication in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study","Inclusion Criteria:\n\n1. Age 12-18 years.\n2. Meet DSM-5 diagnostic criteria for a current depressive episode, as confirmed by the K-SADS-PL.\n3. Children's Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline.\n4. Stable psychotropic medication treatment for at least 4 weeks prior to enrollment and willingness to continue the same regimen throughout the study.\n\nExclusion Criteria:\n\n1. Psychiatric comorbidities other than anxiety disorders.\n2. Depression with psychotic features.\n3. Young Mania Rating Scale (YMRS) score \\>13.\n4. History of neurological disorders (e.g., epilepsy, traumatic brain injury) or severe physical illnesses (e.g., thyroid disease, lupus, diabetes, significant liver, kidney, or lung impairment, major trauma).\n5. Previous treatment with electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), tACS, or other neurostimulation therapies.\n6. Current use of antiepileptic drugs or high-dose benzodiazepines.\n7. History of alcohol or substance abuse or dependence.\n8. Pregnant or breastfeeding females.\n9. Contraindications to MRI.\n10. Current high suicide risk.",{"count":49,"type":21},30,[51],"NA","This randomized, double-blind, sham-controlled pilot study will evaluate the feasibility, acceptability, safety, and preliminary clinical effects of transcranial alternating current stimulation as an adjunctive treatment for adolescents with major depressive disorder. It will also examine changes in depressive symptoms and related clinical outcomes, while exploring potential effects on emotional regulation, cognitive function, and brain function following the intervention.",[27],{"date":31,"type":32},{"date":56,"type":32},"2025-10-01",{"date":58,"type":21},"2027-10-01",{"name":38,"class":39},{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100648171","finerenone-for-the-treatment-of-type-2-diabetes-related-kidney-disease-efficacy-observation-and-related-factor-analysis-100648171","NCT07717697","Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis","Inclusion Criteria:\n\n* Aged 18-75 years, male or female, with full capacity for independent conduct.\n* Confirmed type 2 diabetes-associated chronic kidney disease (CKD): Random urine albumin-to-creatinine ratio (UACR) of 100-5000 ug\u002Fmg Cr on two non-consecutive days; estimated glomerular filtration rate (eGFR) calculated by the CKD-EPI formula \\>25 mL\u002Fmin\u002F1.73m²; Finerenone treatment is indicated per clinical guidelines.\n* All concomitant medications have remained stable for 3 months prior to screening, with no planned treatment adjustments throughout the trial. Stable medication is defined as dose adjustments not exceeding ±25% of the screening baseline dose.\n* If the glycemic regimen includes sodium-glucose cotransporter 2 inhibitors (SGLT-2i): The daily SGLT-2i dose remains constant for 3 months before screening, and no daily dose changes are planned during the entire trial. If the glycemic regimen excludes SGLT-2i: No SGLT-2i exposure within 4 weeks prior to screening, and no SGLT-2i initiation is planned throughout the trial.\n* If the glycemic regimen includes glucagon-like peptide-1 receptor agonists (GLP-1RA): The daily GLP-1RA dose remains constant for 3 months before screening, and no daily dose changes are planned during the entire trial. If the glycemic regimen excludes GLP-1RA: No GLP-1RA exposure within 4 weeks prior to screening, and no GLP-1RA initiation is planned throughout the trial.\n* Fully understands the entire trial procedure, voluntarily participates in the study and signs the informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed or suspected type 1 diabetes, special type diabetes or secondary diabetes.\n* Poor glycemic control with glycated hemoglobin (HbA1c) \\>9.0%.\n* Average seated office blood pressure measured over 3 visits with systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg.\n* Serum potassium \\>5.0 mmol\u002FL without potassium supplementation.\n* Diagnosed or suspected chronic kidney disease unrelated to diabetic nephropathy.\n* Complicated with liver cirrhosis or moderate-to-severe liver impairment.\n* Patients with secondary aldosteronism and primary aldosteronism who have surgery plans within six months.\n* Confirmed Addison's disease.\n* Complicated with uncontrolled autoimmune diseases.\n* Complicated with active malignant tumors.\n* Presence or suspicion of depression, bipolar disorder, suicidal tendency, schizophrenia or other severe mental illnesses; or lack of mental capacity or language barrier, unable to fully understand the trial protocol or unwilling to cooperate with study site staff.\n* Complicated with other uncontrolled chronic diseases.\n* Use of serum potassium-elevating agents (e.g., amiloride, triamterene) or other mineralocorticoid receptor antagonists (MRAs, e.g., spironolactone, eplerenone) within 4 weeks prior to screening.\n* Use of strong CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin, nefazodone) or CYP3A4 inducers (carbamazepine, phenytoin, erythromycin, fluvoxamine) within 2 weeks prior to screening.\n* Pregnant or breastfeeding women.","75 Years",{"count":68,"type":21},425,"OBSERVATIONAL","This is a single-center prospective observational clinical study conducted at the First Affiliated Hospital of Chongqing Medical University. A total of 425 patients aged 18-75 years with type 2 diabetes mellitus-related chronic kidney disease will be enrolled from February 2026 to January 2029. All participants will receive standard finerenone treatment in accordance with clinical guidelines with a 4-month follow-up period. Blood and urine samples will be collected at screening, baseline, 1 month, 2 months and 4 months after treatment initiation for routine biochemistry, aldosterone\u002Frenin testing, captopril suppression test and multi-omics analysis.\n\nParticipants will be categorized into benefit group, partial benefit group and non-benefit group based on the reduction rate of urine albumin-to-creatinine ratio (UACR) at Month 4. We will combine demographic data, laboratory indicators and multi-omics profiles to identify key biomarkers predicting finerenone response, and construct a predictive model to realize precise individualized therapy for diabetic kidney disease.\n\nAll study-related laboratory tests are free of charge for subjects. A priority consultation channel is available during follow-up, and free professional consultation on diabetic nephropathy will be provided. Serum potassium and renal function will be closely monitored to manage safety risks such as hyperkalemia. All personal data and biological samples are anonymized and stored in encrypted systems with strict confidentiality protection. Subjects may withdraw from the study voluntarily at any time without interference to their routine clinical care.",[72,73],"Type 2 Diabetes Mellitus","Diabetic Kidney Disease",[75,76,77,78,79],"Finerenone","Type 2 diabetes mellitus","Diabetic kidney disease","Predictive model","Prospective observational study","NOT_YET_RECRUITING","2026-07-16",{"date":83,"type":32},"2026-07-21",{"date":85,"type":21},"2026-07-30",{"date":87,"type":21},"2029-01-30",{"name":38,"class":39},{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":66,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":40},"100647472","evaluating-the-effectiveness-of-a-smart-screening-and-tiered-management-tool-for-diabetic-kidney-disease-in-primary-care-a-cluster-randomized-trial-100647472","NCT07707518","Evaluating the Effectiveness of a Smart Screening and Tiered Management Tool for Diabetic Kidney Disease in Primary Care: A Cluster Randomized Trial","SMART-DKD","Inclusion Criteria:\n\n* Aged 18-75 years old.\n* Diagnosed with type 2 diabetes mellitus.\n* Able to complete follow-up visits and relevant examinations as required.\n* Voluntary participation with signed informed consent.\n\nExclusion Criteria\n\n* Complicated with severe hepatic, renal, cardiac or malignant tumor diseases.\n* With acute complications of diabetes or severe infectious diseases within 3 months.\n* Pregnant or lactating women.\n* Participating in other similar clinical intervention studies.\n* Unable to cooperate with study management due to cognitive or mental disorders.",{"count":97,"type":21},3000,[51],"This is a cluster-randomized controlled trial aiming to evaluate the effectiveness of an intelligent standardized screening and risk-stratified management tool for diabetic kidney disease (DKD) among adults with type 2 diabetes in primary care settings.\n\nBackground China has a high prevalence of type 2 diabetes, and 30%-40% of diabetic patients develop DKD, the leading cause of end-stage kidney disease. Primary care facilities lack convenient, standardized digital tools to screen, grade and manage DKD systematically, leading to delayed detection and suboptimal kidney protection for diabetic patients. This study develops a localized intelligent DKD management system integrated into primary care electronic medical records (HIS) to solve this gap.\n\nStudy Design \\& Participants\n\nWe will recruit 30 primary healthcare institutions (15 urban community health centers, 15 rural township health centers) across Longyou County, with at least 200 registered type 2 diabetes patients at each site. A total of 3,000 eligible adults aged 18-75 years diagnosed with type 2 diabetes will be enrolled, randomly assigned in a 1:1 cluster ratio to two groups:\n\nIntervention group (15 sites, 1,500 patients): Receive the intelligent DKD screening and graded management plug-in embedded in local HIS. The tool automatically calculates estimated glomerular filtration rate (eGFR), generates DKD risk stratification, sends reminders for regular urine albumin creatinine ratio (UACR) testing, and provides individualized treatment, follow-up and referral guidance.\n\nControl group (15 sites, 1,500 patients): Receive routine standard diabetes management following national primary care diabetes guidelines, without access to the intelligent DKD digital support system.\n\nStudy Procedures All participants complete a baseline screening visit (V1) to sign informed consent, review medical history, complete physical examinations, and undergo lab tests including UACR, serum creatinine, fasting blood glucose, glycated hemoglobin, lipid profile and urinalysis. Follow-up visits are scheduled at 3 months (V2), 6 months (V3), and 12 months (V4) after baseline, repeating physical checks and core laboratory testing. An optional extended observational follow-up continues until 24 months, with biospecimens collected and shipped to the central research laboratory for unified testing. Participants may withdraw voluntarily at any time without impact on routine clinical care, and unscheduled visits will be arranged if adverse events or abnormal lab results occur.\n\nKey Study Outcomes Primary Outcome: Change in log-transformed urine albumin creatinine ratio (UACR) from baseline to the 12-month follow-up, comparing the two management models.\n\nSecondary Outcomes: 12-month DKD screening rate, DKD diagnosis rate, standardized DKD treatment rate, and change in eGFR over 12 months. The study also assesses the operability of the intelligent management tool and patient treatment adherence in primary care.\n\nRisks \\& Benefits Potential Risks: Participants will undergo routine fasting blood draws and urine collection at each visit, which may cause minor temporary pain, bruising, or rare vasovagal reactions during venipuncture.\n\nBenefits: All participants receive free regular DKD-related laboratory testing covered by the research team. Intervention group patients receive personalized, automated kidney risk management recommendations to slow DKD progression. Any study-related injury will receive free medical treatment and corresponding compensation from the research project.\n\nData Protection \\& Ethics All participant personal information and biological samples are fully anonymized with unique study codes and stored in encrypted databases with restricted access. The study strictly complies with the Declaration of Helsinki, Chinese GCP, and domestic clinical research regulations. All participants provide written informed consent before enrollment, with full rights to withdraw at any stage without penalty. Study results will be published in peer-reviewed journals and presented at academic conferences to improve nationwide primary care DKD prevention and control.\n\nStatistical Analysis All analyses will use intention-to-treat, modified intention-to-treat, per-protocol, and safety analysis datasets. Mixed models for repeated measures, t-tests, rank-sum tests, and Fisher's exact tests will be applied to compare between-group differences, with multiple imputation used to handle missing primary endpoint data. All adverse events will be coded using MedDRA and summarized to evaluate the safety profile of the intervention strategy.",[72,73],[102,77,103,104,105],"Type 2 diabetes","Primary care","CDSS","Cluster randomized trial","2026-07-13",{"date":81,"type":32},{"date":85,"type":21},{"date":110,"type":21},"2028-09-30",{"name":38,"class":39},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100646297","effect-of-vexus-score-on-postoperative-pulmonary-complications-in-elderly-patients-100646297","NCT07691944","Effect of VExUS Score on Postoperative Pulmonary Complications in Elderly Patients","Effect of VExUS Score-Guided Intraoperative Goal-Directed Fluid Therapy on Postoperative Pulmonary Complications in Elderly Patients Undergoing McKeown Minimally Invasive Esophagectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 65 and 80 years old\n* Scheduled for elective McKeown MIE\n* ASA physical status classification I to III\n* Body mass index (BMI) between 18 kg\u002Fm² and 30 kg\u002Fm² (exclusive of 18 kg\u002Fm²)\n\nExclusion Criteria:\n\n* Respiratory failure (SaO₂ \\\u003C 60 mmHg and\u002For PaCO₂ \\> 50 mmHg)\n* Severe cardiac dysfunction (NYHA class III-IV)\n* Angina pectoris within the past 3 months or acute myocardial infarction (STEMI\u002FNSTEMI) within the past 6 months\n* Pulmonary hypertension (pulmonary artery systolic pressure, PASP \\> 35 mmHg)\n* Moderate to severe tricuspid stenosis\u002Fregurgitation (valve orifice area \\\u003C 1.5 cm² \u002F vena contracta width ≥ 0.3 cm)\n* Decompensated cirrhosis (Child-Pugh class ≥ B)\n* Chronic kidney disease (CKD stage ≥ 3a) (estimated glomerular filtration rate, eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m²)\n* Cognitive impairment (Mini-Mental State Examination, MMSE \\\u003C 27) and inability to cooperate with follow-up","65 Years","80 Years",{"count":122,"type":21},126,"Brief Summary This clinical trial aims to evaluate whether perioperative goal-directed fluid therapy (GDFT) targeting a venous excess ultrasound (VExUS) score of 1 can reduce postoperative pulmonary complications (PPCs) in elderly patients undergoing McKeown minimally invasive esophagectomy (MIE). The study will also assess postoperative organ microcirculatory perfusion and quality of recovery.\n\nKey research questions the trial seeks to answer include:\n\nDoes VExUS score-guided GDFT reduce the incidence of PPCs in elderly patients following McKeown MIE? Do participants receiving VExUS-guided GDFT achieve better clinical outcomes? Investigators will compare VExUS score-targeted GDFT with fluid therapy guided by the standard Vigileo-FloTrac™ system, to determine if the VExUS-guided approach reduces the occurrence of postoperative pulmonary complications in elderly patients.\n\nParticipant assessments and data collection include:\n\nVExUS score assessment at four time points: preoperatively, after thoracic phase of surgery, after abdominal phase of surgery, and at the end of surgery. Concomitant measurements will include capillary refill time (CRT, in minutes), perfusion index (PI), blood lactate level (Lac, in mmol\u002FL), and central venous oxygen saturation (ScvO₂, in percent).\n\nPostoperative lung ultrasound score assessment. Recording of clinical outcomes including length of intensive care unit (ICU) stay (in days), postoperative hospital length of stay (in days), 30-day postoperative readmission rate due to pulmonary complications (in percent), and in-hospital postoperative mortality rate (in percent).",[125,126],"Esophageal Cancer (EsC)","Postoperative Pulmonary Complications (PPCs)","2026-07-07",{"date":129,"type":32},"2026-07-09",{"date":131,"type":21},"2026-08-01",{"date":133,"type":21},"2026-12-31",{"name":38,"class":39},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100634447","phase-2-efficacy-and-safety-of-sertraline-combined-with-lactobacillus-crispatus-in-adolescents-with-depression-100634447","NCT07539805","Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression","Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression : A Multicenter Randomized Controlled Trial","Inclusion criteria\n\n* Aged 12-18 years\n* Meets DSM-5 criteria for major depressive disorder (MDD) and is currently in a depressive episode according to the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL) interviews\n* Child Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline\n* Clinical Global Impression Scale (CGI-S) score ≥ 4 at baseline\n\nExclusion criteria\n\n* Presence of any comorbid psychiatric disorder according to DSM-5, other than anxiety disorders\n* MDD with psychotic symptoms\n* Young Mania Rating Scale (YMRS) \\>13 at baseline\n* History of neurological disorders (e.g., epilepsy, traumatic brain injury), or the presence of serious physical illnesses (e.g., thyroid disease, lupus erythematosus, diabetes mellitus, clinically significant pulmonary, hepatic, or renal impairment, or major trauma)\n* Nonresponse to at least two antidepressants with different mechanisms, and each administered at an adequate dose and for an adequate duration\n* History of intolerance to sertraline or nonresponse to an adequate therapeutic course of sertraline\n* Current high suicide risk\n* History of alcohol or drug abuse or dependence\n* Taking or administering antidepressants within 5 half-lives\n* Use of probiotic-related food or medicine within 2 weeks before enrollment\n* Systemic use of antibiotics or antifungals within 1 month before enrollment\n* History of severe food allergy or known hypersensitivity to the Lactobacillus crispatus preparation or any of its components\n* Adherence to vegetarian or other restrictive dietary patterns\n* Pregnancy or breastfeeding",{"count":143,"type":21},60,[24],"The goal of this clinical trial is to evaluate the efficacy and safety of sertraline combined with Lactobacillus crispatus in adolescents aged 12-18 years with major depressive disorder. The main question it aims to answer is: Whether sertraline combined with Lactobacillus crispatus is superior to sertraline combined with placebo in reducing depressive symptoms and improving emotional symptoms in adolescents with depression.\n\nIf there is a comparison group: Researchers will compare sertraline combined with Lactobacillus crispatus with sertraline combined with placebo ( look-alike substance that contains no probiotics) to determine whether the addition of Lactobacillus crispatus provides greater therapeutic benefit in adolescents with depression.\n\nParticipants will: 1. Receive sertraline combined with Lactobacillus crispatus or sertraline combined with placebo for 8 weeks; 2. Attend clinic visits every 4 weeks for clinical assessments and safety monitoring",[147,148],"Major Depressive Disorder (MDD)","Probiotic Intervention","2026-06-11",{"date":151,"type":32},"2026-06-15",{"date":149,"type":32},{"date":154,"type":21},"2028-04",{"name":38,"class":39},2,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":40},"100643411","phase-2-sertraline-combined-with-multi-strain-probiotics-for-adolescent-depression-100643411","NCT07645157","Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression","A Study on the Efficacy and Safety of Sertraline Combined With Multi-Strain Probiotics in Treating Adolescent Patients With Depression: A Multi-Center Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* • Aged 12-18 years\n\n  * Meets DSM-5 criteria for major depressive disorder (MDD) and is currently in a depressive episode according to the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL) interviews\n  * Child Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline\n  * Clinical Global Impression Scale (CGI-S) score ≥ 4 at baseline\n\nExclusion Criteria:\n\n* • Presence of any comorbid psychiatric disorder according to DSM-5, other than anxiety disorders\n\n  * MDD with psychotic symptoms\n  * Young Mania Rating Scale (YMRS) \\>13 at baseline\n  * History of neurological disorders (e.g., epilepsy, traumatic brain injury), or the presence of serious physical illnesses (e.g., thyroid disease, lupus erythematosus, diabetes mellitus, clinically significant pulmonary, hepatic, or renal impairment, or major trauma)\n  * Nonresponse to at least two antidepressants with different mechanisms, and each administered at an adequate dose and for an adequate duration\n  * History of intolerance to sertraline or nonresponse to an adequate therapeutic course of sertraline\n  * Current high suicide risk\n  * History of alcohol or drug abuse or dependence\n  * Taking or administering antidepressants within 5 half-lives\n  * Use of probiotic-related food or medicine within 2 weeks before enrollment\n  * Systemic use of antibiotics or antifungals within 1 month before enrollment\n  * History of severe food allergy or known hypersensitivity to the Lactobacillus crispatus preparation or any of its components\n  * Adherence to vegetarian or other restrictive dietary patterns\n  * Pregnancy or breastfeeding",{"count":165,"type":21},120,[24],"The objective of this clinical trial is to evaluate the efficacy and safety of sertraline combined with multi-strain probiotics in adolescents aged 12-18 with major depressive disorder. The primary research question is whether sertraline combined with multi-strain probiotics is superior to sertraline combined with placebo in alleviating depressive symptoms and improving mood symptoms in adolescents. If there is a control group: researchers will compare sertraline combined with multi-strain probiotics with sertraline combined with placebo (a substance that looks similar but does not contain probiotics) to determine whether adding multi-strain probiotics provides greater therapeutic benefits for adolescent patients with depression. Participants will: 1. Undergo 8 weeks of treatment with sertraline combined with multi-strain probiotics or sertraline combined with placebo; 2. Have clinical visits every 4 weeks for clinical assessments and safety monitoring.",[147,148],"2026-06-09",{"date":171,"type":32},"2026-06-12",{"date":173,"type":21},"2026-10-01",{"date":175,"type":21},"2028-10-01",{"name":38,"class":39},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":40},"100607198","feasibility-safety-and-preliminary-clinical-efficacy-of-magnetic-resonance-imaging-guided-repetitive-transcranial-magnetic-stimulation-rtms-in-adolescents-with-depression-a-randomized-double-blind-controlled-pilot-study-100607198","NCT07185438","Feasibility, Safety, and Preliminary Clinical Efficacy of Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study","Inclusion Criteria:\n\n1. Age 12 - 18\n2. Diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed through the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime version (K-SADS-PL), currently in a depressive episode\n3. Score≥40 on the CDRS-R\n4. Stable pharmacological treatment: At least 4 weeks of stable psychiatric medication use prior to enrollment, with continuation of the same psychiatric medication regimen throughout the study.\n\nExclusion Criteria:\n\n1. Psychiatric comorbidities other than anxiety disorders\n2. Depression with psychotic symptoms\n3. Young Mania Rating Scale (YMRS) score \\>13\n4. A history of neurological disorders (e.g., epilepsy, brain injury) or severe somatic diseases (e.g., thyroid disorders, lupus, diabetes, pulmonary, hepatic, or renal impairment, major trauma)\n5. Patients currently using anticonvulsants or high-dose benzodiazepines\n6. A history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neuromodulation treatments\n7. A history of alcohol or substance abuse or dependence\n8. Women who are pregnant or breastfeeding\n9. Current high suicide risk\n10. Potential complicating factors related to transcranial magnetic stimulation, such as scalp conditions or perforations that may affect magnetic field delivery\n11. Contraindications to MRI",{"count":184,"type":21},45,[51],"This study aims to assess the feasibility, safety, acceptability, and preliminary efficacy trends of a Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) intervention for adolescent depression through a pilot clinical trial. The findings will inform the design and optimization of subsequent formal randomized controlled trials, providing essential evidence for their execution.",[27],"2026-05-20",{"date":190,"type":32},"2026-05-26",{"date":192,"type":32},"2025-09-15",{"date":194,"type":21},"2027-12-30",{"name":38,"class":39},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":4},"100631334","talquetamab-in-patients-with-refractory-generalized-myasthenia-gravis-100631334","NCT07499323","Talquetamab in Patients With Refractory Generalized Myasthenia Gravis","A Preliminary Case Study to Evaluate the Efficacy and Safety of Talquetamab in Patients With Refractory Generalized Myasthenia Gravis","Inclusion Criteria:\n\n* The patient must sign the informed consent form for participation in the study and agree to comply with the study procedures.\n* Age 18-70 years.\n* Must meet the clinical diagnostic criteria for MG, defined as presenting with a typical pattern of weakness (predominantly affecting proximal muscles, fatiguability, fluctuating severity, worse with prolonged effort and better after rest) and meeting any one of the following three conditions: documented history of abnormal neuromuscular transmission confirmed by single-fiber electromyography or repetitive nerve stimulation; documented history of a positive neostigmine test; or improvement in MG signs following oral administration of an acetylcholinesterase inhibitor. Additionally, the Myasthenia Gravis Foundation of America (MGFA) clinical classification must be II-IV, and the patient must be positive for anti-AChR antibodies.\n* Must meet the definition of \"refractory myasthenia gravis\" according to the Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis (2025 Edition): defined as having a suboptimal response to conventional immunotherapeutic drugs, intolerance to or having contraindications for adverse drug reactions, or experiencing frequent disease relapses requiring regular rescue therapy, making it difficult to achieve treatment goals.\n* Myasthenia Gravis Activities of Daily Living (MG-ADL, Appendix 1) score ≥6, with \\>50% of the score derived from non-ocular items.\n* Quantitative Myasthenia Gravis (QMG) score (Appendix 2) ≥8, with \\>50% of the score derived from non-ocular items.\n* The dosage of pyridostigmine bromide must be stable for at least 1 week prior to the treatment period.\n\nExclusion Criteria:\n\n* Patients who have had their glucocorticoid dose adjusted, or who have received immunoglobulins, plasma exchange, neonatal Fc receptor inhibitors, or complement inhibitors within ≤4 weeks.\n* Patients who have undergone thymectomy, received B-cell depletion therapy, or had their dose of non-steroidal immunosuppressants (such as azathioprine, tacrolimus, mycophenolate mofetil, cyclophosphamide, etc.) adjusted within ≤3 months.\n* Patients who have participated in any interventional clinical trial or received investigational treatment within ≤3 months, or within 5 half-lives of the received investigational drug (whichever is longer).\n* Patients with concurrent severe liver, kidney, cardiac, pulmonary, or coagulation dysfunction.\n* Patients with concurrent chronic infections such as Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, or Mycobacterium tuberculosis.","70 Years",{"count":156,"type":21},[51],"Myasthenia Gravis (MG) is a chronic autoimmune disease mediated by pathogenic antibodies. Approximately 10%-15% of patients present with refractory status, defined as having an inadequate response to existing therapies or an inability to tolerate the side effects of the medication, highlighting an urgent need for the development of more targeted innovative therapies. Talquetamab is a bispecific antibody that targets G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and the Cluster of Differentiation 3 (CD3) molecule on the surface of T cells, thereby inducing T cells to precisely eliminate GPRC5D-positive cells. This study will conduct an exploratory case series to investigate the efficacy and safety of Talquetamab in refractory MG.",[208],"Myasthenia Gravis (MG)","2026-04-03",{"date":211,"type":32},"2026-04-08",{"date":213,"type":21},"2026-03-20",{"date":36,"type":21},{"name":38,"class":39},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":40},"100537260","safety-and-efficacy-of-multisensory-stimulation-virtual-reality-for-stroke-patients-100537260","NCT06275516","Safety and Efficacy of Multisensory Stimulation Virtual Reality for Stroke Patients.","A Single-blind Randomized Controlled Trial of Multisensory Stimulation Virtual Reality to Improve Motor and Cognitive Function in Stroke Patients","Inclusion Criteria:\n\n1. The first onset of stroke is diagnosed and confirmed according to the requirements of stroke\n2. The Fugl-Meyer Assessment of Lower Extremity (FMA-LE) is less than 34.\n3. 18-85 years of age.\n4. Able to walk with minor assistance\n5. MMSE score of 20-30 and ability to understand and follow instructions during the trial\n6. Able to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe visual or hearing impairments.\n2. Pregnant or breastfeeding women.\n3. Patients with unrepaired cranial bone flaps or metallic implants following brain surgery.\n4. Presence of other conditions affecting lower limb motor function, such as osteoarthritis or recent lower limb fractures.\n5. History of severe psychiatric disorders, other neurological diseases, acute cardiopulmonary dysfunction, multiple organ failure, brain tumours, or epilepsy.","85 Years",{"count":225,"type":21},40,[51],"This was a single-blind randomized controlled trial of multisensory stimulation virtual reality to improve motor and cognitive dysfunction in stroke patients.",[229],"Stroke","2026-03-16",{"date":232,"type":32},"2026-03-19",{"date":234,"type":32},"2024-03-20",{"date":85,"type":21},{"name":38,"class":39},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":16,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":256,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":40},"100628425","effects-of-continuous-monitoring-and-progressive-regulation-of-inflatable-laryngeal-mask-airway-cuff-pressure-on-postoperative-pharyngolaryngeal-complications-in-elderly-patients-100628425","NCT07461467","Effects of Continuous Monitoring and Progressive Regulation of Inflatable Laryngeal Mask Airway Cuff Pressure on Postoperative Pharyngolaryngeal Complications in Elderly Patients","Inclusion Criteria:\n\n* Aged ≥ 60years;\n* Non-cardiac, non-thoracic, and non-head and neck surgery;\n* Non-laparoscopic surgery;\n* Elective surgery;\n* Surgical position: supine position ;\n* American Society of Anesthesiologists (ASA) physical status classification Ⅰ-Ⅲ;\n* New York Heart Association (NYHA) cardiac function classification Ⅰ-Ⅱ;\n* Expected surgical duration ≥30 minutes and ≤ 2 hours;\n* Body mass index (BMI) 18.5-30.0 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Preoperative predictable difficult airways, such as trismus, limited neck mobility, and other related conditions;\n* Preoperative pharyngeal and laryngeal complications including sore throat, hoarseness, blood-tinged sputum, and dysphagia;\n* Preexisting conditions such as loose teeth, laryngeal obstruction, laryngeal edema, acute airway inflammation, and gastrointestinal bleeding;\n* Comorbidities of respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma;\n* Allergies to ILMA materials (e.g., silicone, polyvinylchloride \\[PVC\\]);\n* Inability to cooperate with the study for any reason;\n* Participation in other clinical trials within 3 months prior to enrollment in this study;\n* Any other circumstances deemed inappropriate for inclusion by the investigators.","60 Years",{"count":245,"type":21},146,[51],"Currently, research on laryngeal mask airway (LMA) has been continuously deepened both domestically and internationally, which has greatly promoted the optimization process of clinical application and related management strategies. Numerous domestic and foreign research findings have consistently emphasized the key role of LMA cuff pressure monitoring in reducing postoperative complications, especially in alleviating sore throat and dysphagia. Foreign studies have extensively covered the research and development innovation of LMA devices, as well as comprehensive comparative analyses with other airway management methods such as endotracheal intubation, providing rich perspectives for expanding the application of LMA and improving its application effects. In contrast, domestic studies have distinct pertinence, focusing on application exploration in specific populations and clinical practice scenarios, and have provided important evidence for the safe and effective use of LMA in specific groups through in-depth research. However, it is undeniable that there are obvious deficiencies in both domestic and foreign research regarding the application of continuous monitoring and progressive regulation of LMA cuff pressure in elderly patients-a crucial field. Due to the natural decline of physiological functions, elderly patients face an increased risk of complications such as pulmonary and extrapulmonary complications, as well as pharyngolaryngeal complications, when using LMA during the perioperative period. Therefore, it is particularly urgent to carry out continuous pressure monitoring and progressive regulation of LMA cuff pressure, and to further explore the optimal range of LMA cuff pressure. This study will not only fill the current research gap but also provide solid support for the safe and efficient airway management of elderly patients during the perioperative period.",[249,250,251,252,253,254,255],"Elderly (People Aged 65 or More)","LMA","Randomized Controlled Trial","Laryngeal Mask Airways","Pharyngolaryngeal Postoperative Pain","Cuff Pressure","Oropharyngeal Leak Pressure",[257,258,259,260,251],"Elderly people","Laryngeal mask airways","pharyngolaryngeal complications","cuff pressure","2026-03-06",{"date":263,"type":32},"2026-03-10",{"date":265,"type":32},"2025-11-02",{"date":267,"type":21},"2027-03-01",{"name":38,"class":39},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":284,"leadSponsor":286,"locationsCount":40},"100621368","efficacy-and-safety-of-accelerated-intermittent-theta-burst-stimulation-a-itbs-in-adolescents-with-depressive-disorder-100621368","NCT07369713","Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation (a-iTBS) in Adolescents With Depressive Disorder","Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation (a-iTBS) in Adolescents With Depressive Disorder: A Randomized, Double-Blind, Controlled Pilot Study","Inclusion Criteria:\n\n(1) Age 12 - 18 (2) Diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed through the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime version (K-SADS-PL), currently in a depressive episode (3) Score≥40 on the CDRS-R (4) Stable pharmacological treatment: At least 4 weeks of stable psychiatric medication use prior to enrollment, with continuation of the same psychiatric medication regimen throughout the study.\n\n\\-\n\nExclusion Criteria:\n\n1. Psychiatric comorbidities other than anxiety disorders\n2. Depression with psychotic symptoms\n3. Young Mania Rating Scale (YMRS) score \\>13\n4. A history of neurological disorders (e.g., epilepsy, brain injury) or severe somatic diseases (e.g., thyroid disorders, lupus, diabetes, pulmonary, hepatic, or renal impairment, major trauma)\n5. Patients currently using anticonvulsants or high-dose benzodiazepines\n6. A history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neuromodulation treatments\n7. A history of alcohol or substance abuse or dependence\n8. Women who are pregnant or breastfeeding\n9. Current high suicide risk\n10. Potential complicating factors related to transcranial magnetic stimulation, such as scalp conditions or perforations that may affect magnetic field delivery\n11. Contraindications to MRI -",{"count":184,"type":21},[51],"This study aims to assess the feasibility, safety, acceptability, and preliminary efficacy trends of a Accelerated Intermittent Theta-burst Stimulation (a-iTBS) intervention for adolescent depression through a pilot clinical trial. The findings will inform the design and optimization of subsequent formal randomized controlled trials, providing essential evidence for their execution.",[27],"2026-03-02",{"date":282,"type":32},"2026-03-04",{"date":131,"type":21},{"date":285,"type":21},"2028-08-01",{"name":38,"class":39},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":120,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":40},"100603201","phase-4-mecobalamin-combined-with-anti-vegf-intravitreal-injection-for-retinal-vein-occlusion-treatment-100603201","NCT07133438","Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment","Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Treatment Retinal Vein Occlusion: a Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\nDiagnosis of RVO meeting the international diagnostic criteria 4,12, age 18-80 years, gender not limited Treatment-naive RVO-ME (no prior anti-VEGF, glucocorticoid, or laser therapy) The CST is confirmed to be ≥300μm by OCT The baseline BCVA (ETDRS letter count) was 20\u002F400 to 20\u002F40 (34-78 letters) Signed informed consent and ability to comply with follow-up.\n\nExclusion Criteria:\n\nCombined with other eye diseases that cause ME (such as diabetic retinopathy, uveitis) Media opacities affecting imaging (such as severe cataract, vitreous hemorrhage) Prior anti-VEGF, steroid, or macular laser therapy Systemic use of glucocorticoids or immunosuppressants within 3 months Uncontrolled systemic disease (hypertension, diabetes, hepatic\u002Frenal dysfunction); pregnant or lactating women Allergy to mecobalamin or conbercept Unable to cooperate with examinations or follow-up, or participate in other clinical trials within one year",{"count":165,"type":21},[296],"PHASE4","Retinal vein occlusion (RVO), a common retinal vascular disease, is frequently treated with anti-vascular endothelial growth factor (anti-VEGF) agents as first-line therapy. However, anti-VEGF monotherapy lacks neuroprotective effects, primarily targets vascular leakage and neovascularization, and requires frequent long-term injections that impose substantial economic burdens. Combined therapeutic strategies addressing both vascular pathology and neural damage are therefore being explored.\n\nThis article describes the protocol for a randomized, outcome-blinded, placebo-controlled clinical trial evaluating mecobalamin (a widely used neuroprotective drug) in combination with anti-VEGF for the treatment of macular edema (ME). A total of 120 eligible RVO patients will be enrolled from the First Affiliated Hospital of Chongqing Medical University. Participants will be randomly assigned (1:1) to an experimental group and a control group. The experimental group will receive conventional anti-VEGF therapy plus oral mecobalamin capsules for 6 months, while the control group will receive the same anti-VEGF treatment plus a placebo for 6 months. All patients will undergo one year of follow-up after initial treatment, with visits at 1, 3, 6, 9, and 12 months.\n\nThe primary outcome is the change in central subfield thickness (CST) from baseline to one year post-initial treatment. Secondary outcomes include:\n\n* Change in best-corrected visual acuity (BCVA) from baseline over time,\n* Capillary density,\n* Cone photoreceptor distribution characteristics,\n* Mean light sensitivity and fixation stability,\n* Serum vitamin B12 levels,\n* Number of anti-VEGF treatments,\n* Injection frequency (times per year),\n* Treatment interval,\n* Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).\n\nThis trial evaluates a novel \"neuroprotection + vascular intervention\" strategy combining mecobalamin with anti-VEGF therapy. The trial aims to provide high-level evidence for synergistic RVO treatment, with the potential to reduce recurrence rates and improve long-term visual function prognosis.",[299],"Retinal Vein Occlusion (RVO)",[299,301,302],"Macular edema","Anti-VEGF","2026-02-24",{"date":305,"type":32},"2026-02-27",{"date":307,"type":32},"2025-08-01",{"date":309,"type":21},"2027-07-31",{"name":38,"class":39},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":318,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":319,"targetDuration":320,"studyType":69,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":40},"100624456","an-integrated-multi-omics-study-on-the-molecular-mechanisms-of-ureteral-stricture-100624456","NCT07409870","An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture","US-MOP","Inclusion Criteria (Ureteral Stricture Group):\n\nAge between 18 and 75 years, regardless of gender. Diagnosis of ureteral stricture confirmed by clinical symptoms and imaging (e.g., CT, IVP, or retrograde pyelography) or ureteroscopy.\n\nThe patient is scheduled for or undergoing standard clinical evaluation\u002Ftreatment for ureteral stricture.\n\nWillingness to provide stool, urine, and blood samples. Informed consent signed by the participant or their legal representative.\n\nInclusion Criteria (Healthy Control Group):\n\nAge- and sex-matched volunteers (18-75 years). No history of ureteral stricture, urinary tract obstruction, or significant renal disease.\n\nPhysical examination and laboratory tests (renal function, routine urine analysis) are within normal limits.\n\nExclusion Criteria (Applicable to Both Groups):\n\nUse of antibiotics, probiotics, prebiotics, or antifungal medications within the 4 weeks prior to sample collection.\n\nHistory of chronic gastrointestinal diseases (e.g., Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), or chronic diarrhea).\n\nKnown malignant tumors of the urinary tract or other systemic malignancies. History of major abdominal or urinary tract surgery within the last 3 months (excluding the current planned procedure for patients).\n\nPresence of severe systemic diseases, including uncontrolled diabetes, severe hepatic dysfunction, or end-stage heart failure.\n\nPregnancy or breastfeeding. Any other condition that, in the opinion of the investigator, may interfere with the microbiome or metabolomic analysis.",true,{"count":165,"type":21},"3 Months","The goal of this observational study is to investigate the systemic pathogenesis and identify potential diagnostic biomarkers in patients with ureteral stricture and healthy volunteers. The main questions it aims to answer are:\n\nWhat are the systemic differences in the gut microbiome, urine microbiome, and metabolomic profiles (fecal, urinary, and serum) between patients with ureteral stricture and healthy controls? What are the correlations between these microbial\u002Fmetabolic alterations and clinical phenotypes, such as stricture severity, inflammatory levels, and renal function? Researchers will compare the biological panoramic profiles of patients with ureteral stricture to those of healthy controls to see if specific \"microbiome-metabolite-disease\" regulatory networks drive the development of the condition.\n\nParticipants will:\n\nProvide stool samples for gut microbiome (16S\u002FMetagenomics) and metabolomic analysis.\n\nProvide urine samples for urine microbiome and metabolomic analysis. Provide blood (serum) samples for systemic metabolomic profiling. Undergo clinical assessments, including medical history collection, imaging (e.g., CT\u002FIVP), and laboratory tests (e.g., renal function, inflammatory markers) to evaluate disease severity.",[323,324,325,326],"Ureteral Stricture","Ureteral Obstruction","Microbiome","Metabolomics","2026-02-07",{"date":329,"type":32},"2026-02-13",{"date":331,"type":21},"2026-02-01",{"date":333,"type":21},"2026-07-31",{"name":38,"class":39},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":40},"100605476","digital-cognitive-behavioral-therapy-for-chinese-adolescents-with-depressive-symptomscads-d--100605476","NCT07163013","Digital Cognitive Behavioral Therapy for Chinese Adolescents With Depressive Symptoms（CADS-D )","Digital Cognitive Behavioral Therapy for Chinese Adolescents With Depressive Symptoms（CADS-D ): A Randomized Clinical Trial","CADS-D","Inclusion Criteria:\n\n1. Age 12 to 18 years;\n2. Scored 28 or higher on the children's depression rating scale-revised (CDRS-R);\n3. Have the ability to read and write in Chinese;\n4. Participant and at least one of their guardians provided written consent;\n5. Have access to mobile phone and internet.\n\nExclusion Criteria:\n\n1. The researchers assessed that the adolescent's depressive symptoms were too severe to participate to CADS-D;\n2. Scored 5 or higher on item 13 (suicidal ideation) on CDRS-R;\n3. Participants who met diagnosis of other mental disorder except depression;\n4. Severe physical illnesses or other physical disabilities that prevented the use of DCBT;\n5. Within the past three months or currently undergoing any antidepressant treatment, including medication therapy, psychotherapy, and physical therapy;\n6. Unavailability to follow up months after intervention.",{"count":344,"type":21},200,[51],"CADS-D aimes to evaluate the effectiveness and feasibility of a newly DCBT program for Chinese adolescents with depressive symptoms.",[348],"Depressive Symptom",[350,351,352],"Depressive symptoms","Digital cognitive behavioral therapy","Adolescent","2026-01-25",{"date":355,"type":32},"2026-01-27",{"date":357,"type":32},"2025-05-12",{"date":359,"type":21},"2026-09",{"name":38,"class":39},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":16,"minAge":369,"maxAge":18,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":40},"100501852","phase-1-sequenced-treatment-alternatives-to-relieve-adolescent-depression-star-ad-100501852","NCT05814640","Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD): a Pragmatic Clinical Trial","STAR-AD","Inclusion Criteria:\n\n1. Age 13 - 18\n2. As assessed by K-SADS-PL, it meets the DSM-V criteria for MDD with non-psychotic symptoms\n3. Score≥40 on the CDRS-R\n4. Participants with suicidal ideation are eligible, as long as clinicians consider outpatient treatment to be safe\n5. Sufficient audio-visual level to complete this study\n6. Written informed consent was obtained from patients and at least one of their parents\n\nExclusion Criteria:\n\n1. History of bipolar disorder, schizophrenia, autism, eating disorders, primary obsessive compulsive disorder, pervasive developmental disorder, or psychosis not otherwise specified\n2. History of serious physical illnesses\n3. Substance abuse or dependence\n4. Current depressive episode with clear suicidal plans or suicidal behavior\n5. Requires inpatient treatment for psychiatric disorders\n6. Severe mental disorders requiring\n7. 2 or more failed trials of antidepressant drugs: each trial for at least 8 weeks, with the last 4 weeks at full dose (e.g. fluoxetine 40mg\u002Fd, citalopram 40mg\u002Fd, escitalopram 20mg\u002Fd, sertraline 150mg\u002Fd )\n8. History of clear-cut intolerability of, or lack of effect with, an adequate trial of at least one protocol treatment option\n9. Taking any medicine that contraindicates in combination with or interferes with the efficacy of the treatment\n10. Taking or administering antidepressants within 5 half-lives\n11. Received modified electroconvulsive therapy within 12 months\n12. If female, is pregnant","13 Years",{"count":371,"type":21},520,[373,24],"PHASE1","This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.",[376,377],"Depression","Sequestra",{"date":355,"type":32},{"date":380,"type":32},"2023-02-20",{"date":382,"type":21},"2027-07-01",{"name":38,"class":39},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":66,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":40},"100617888","phase-2-ivarmacitinib-combined-with-camrelizumab-and-apatinib-for-unresectable-advanced-hepatocellular-carcinoma-with-acquired-resistance-to-immune-checkpoint-therapy-a-single-arm-exploratory-clinical-study-100617888","NCT07324473","Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study","Inclusion Criteria:\n\n1. Patients with a diagnosis of hepatocellular carcinoma, confirmed either by clinical diagnosis (per the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer \\[2022 Edition\\]) or by pathological diagnosis.\n2. Patients classified as Barcelona Clinic Liver Cancer (BCLC) stage B and assessed by the responsible hepatobiliary surgeon as unsuitable for radical resection, or patients with BCLC stage C disease.\n3. Patients with unresectable hepatocellular carcinoma who have developed secondary (acquired) drug resistance. This is defined as having received at least 4 cycles of a first-line targeted therapy combined with immunotherapy regimen recommended by guidelines . Eligible prior regimens include specified combinations (e.g., Camrelizumab + Apatinib; Atezolizumab + Bevacizumab; Sintilimab + Bevacizumab) or other guideline-recommended first-line targeted agents (Donafenib, Lenvatinib, Sorafenib, Cabozantinib, Regorafenib) combined with first-line immunotherapy (Tislelizumab, Durvalumab, Pembrolizumab). Furthermore, patients must have achieved a partial response in the primary lesion but subsequently experienced disease progression after the 4th immunotherapy cycle, as confirmed per RECIST 1.1 criteria (including increase in size of primary lesion, or emergence of new lesions\u002Fmetastases).\n4. At least one measurable lesion according to RECIST 1.1 criteria (target lesion with longest diameter ≥ 10 mm, or lymph node with short axis ≥ 15 mm).\n5. Anticipated life expectancy \\> 3 months.\n6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n7. Adequate organ and bone marrow function, as evidenced by the following laboratory values within 7 days prior ： (1)Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL in the absence of granulocyte colony-stimulating factor support within the last 14 days; (2)Platelets ≥ 60 × 10⁹\u002FL without transfusion within the last 14 days; (3)Hemoglobin \\> 9 g\u002FdL without transfusion or erythropoietin use within the last 14 days; (4)Total bilirubin ≤ 2 × upper limit of normal (ULN); (5)Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; (6)Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥ 60 mL\u002Fmin; (7)Adequate coagulation function, defined as an International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; (8)Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, study participants may still be enrolled if total T3 (or free T3) and free T4 are within the normal range; (9)Myocardial enzyme profile within normal limits (isolated laboratory abnormalities judged by the investigator as clinically insignificant are also permitted);\n8. For female study participants of childbearing potential, a negative urine or serum pregnancy test must be obtained within 3 days prior to the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result is not confirmatory, a serum pregnancy test is required. A female not of childbearing potential is defined as being postmenopausal for at least 1 year, or surgically sterilized, or having undergone a hysterectomy.\n\nExclusion Criteria:\n\n* 1\\. Diagnosis of malignancies other than liver cancer within 5 years prior to the first dose.\n\n  2\\. Intrahepatic or extrahepatic cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, fibrolamellar HCC, ampullary tumors, or other biliary tract malignancies.\n\n  3\\. Prior treatment with any JAK inhibitor.\n\n  4\\. Patients with pleural effusion, ascites, or pericardial effusion requiring drainage, who are clinically assessed as unable to tolerate the study treatment.\n\n  5\\. History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months prior to the first dose; or current imaging (contrast-enhanced CT or MRI) confirming significant esophageal or gastric varices.\n\n  6\\. History of severe bleeding tendency or coagulopathy; clinically significant hemorrhagic symptoms within 1 month prior to the first dose (including but not limited to gastrointestinal bleeding, hemoptysis, epistaxis)\n\n  7\\. History of myocarditis, cardiomyopathy, or malignant arrhythmia\n\n  8\\. History of immunodeficiency; positive HIV antibody test; current long-term use of systemic corticosteroids or other immunosuppressants; active autoimmune disease requiring systemic treatment within the past two years.\n\n  9\\. Known active tuberculosis (TB).\n\n  10\\. Known active syphilis infection.\n\n  11\\. Administration of a live or live-attenuated vaccine within 30 days prior to the first dose.\n\n  12\\. History of mental illness, drug abuse, alcoholism, or substance abuse.\n\n  13\\. Pregnant or lactating women.",{"count":391,"type":21},65,[24],"Background： Hepatocellular carcinoma (HCC) stands as a formidable global health challenge. It ranks as the sixth most common malignant solid tumor worldwide and the third leading cause of cancer-related mortality. The disease is characterized by its insidious onset, rapid progression, and high recurrence rates, contributing to a dismal 5-year survival rate of approximately 18%. A critical factor in this poor prognosis is that nearly 57% of patients are diagnosed at an advanced stage, where curative surgical resection is no longer feasible. For these patients with unresectable advanced HCC (uHCC), effective systemic therapies are paramount to extend survival and improve quality of life.\n\nThe advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting the PD-1\u002FPD-L1 axis, has revolutionized the treatment landscape for numerous advanced cancers, including uHCC. These agents work by blocking the inhibitory signals that tumor cells exploit to evade immune surveillance, thereby reactivating cytotoxic T cells to attack the cancer.\n\nHowever, the clinical benefit of ICI-based therapies is not universal. A substantial proportion of patients-estimated between 15% to 40%-derive limited or no benefit. Primary resistance is defined as a lack of initial response, while acquired resistance refers to disease progression after an initial period of clinical benefit. There is no established, evidence-based standard of therapy for uHCC patients who progress following first-line ICI combination therapy, highlighting an urgent need for novel therapeutic approaches.\n\nThe mechanisms underlying acquired resistance to ICIs are multifaceted and intricately linked to dynamic remodeling of the tumor immune microenvironment (TME). Several key pathways contribute:\n\n1. Loss of Tumor Immunogenicity: Immune editing during treatment can select for tumor cell clones with low neoantigen expression, making them less visible to the immune system.\n2. Immune Suppressive Cell Infiltration: The TME in resistant tumors often exhibits an accumulation of immunosuppressive cell populations, including regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs). These cells create a profoundly inhibitory milieu that dampens anti-tumor T cell function.\n3. T Cell Exhaustion: Persistent antigen exposure leads to a state of CD8⁺ T cell exhaustion, rendering them dysfunctional.\n\nThese interconnected mechanisms collectively foster an immunosuppressive TME that allows tumors to evade ongoing immune attack, underscoring the need for combination strategies that can reshape the TME and re-sensitize tumors to immunotherapy.\n\nThe JAK-STAT pathway serves as a critical signaling hub for numerous cytokines and growth factors, playing a pivotal dual role in immunity and inflammation. In the context of HCC and ICI resistance, its activation is particularly relevant:\n\n1. Pathway Activation in HCC: The JAK\u002FSTAT pathway is ubiquitously activated in both primary and recurrent HCC tumors and contributes to the proliferation and survival of tumor-initiating cells.\n2. Driver of an Immunosuppressive TME: Hyperactivation of this pathway, often via cytokines like IL-6, promotes the recruitment and activation of immunosuppressive MDSCs and M2-polarized TAMs. It also contributes to T cell exhaustion.\n3. Preclinical and Clinical Proof-of-Concept: In preclinical models, JAK\u002FSTAT inhibition has been shown to reduce MDSC infiltration and restore T cell function. Most compellingly, recent clinical studies in other cancer types published in high-impact journals like Science (2024) have demonstrated that adding a JAK inhibitor to PD-1 blockade can re-sensitize tumors and yield significant clinical responses in patients who had developed resistance to immunotherapy alone\n\nPurpose:\n\nThis single-arm, exploratory clinical study aims to evaluate the efficacy and safety of Ivarmacitinib (a selective JAK1 inhibitor) combined with Camrelizumab (anti-PD-1) and Apatinib (anti-VEGFR2) in patients with advanced unresectable HCC who have progressed after first-line ICI-based combination therapy.\n\nMethods:\n\nThis study plans to enroll 65 patients with advanced unresectable hepatocellular carcinoma (unresectable BCLC stage B or stage C) who have been clinically or pathologically diagnosed, have previously received at least 4 cycles of guideline-recommended first-line targeted therapy combined with PD-1\u002FPD-L1 immunotherapy, achieved a partial response, but subsequently experienced disease progression confirmed by RECIST 1.1 criteria after at least 4 cycles (indicating acquired resistance).\n\nAll enrolled patients will receive triple therapy consisting of Ivarmacitinib + Apatinib + Camrelizumab. Treatment will continue until disease progression, unacceptable toxicity, or for up to 2 years.",[395,396,397,398],"Hepatocellular Carcinomas","Resistance to Immunotherapy","Immunomodulation","Drug Repurposing","2025-12-24",{"date":401,"type":32},"2026-01-07",{"date":403,"type":21},"2026-01-01",{"date":405,"type":21},"2029-01-01",{"name":38,"class":39},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":427,"locationsCount":156},"100614133","phase-1-the-effects-of-vonoprazan-fumarate-on-dgf-incidence-in-dd-kidney-transplant-recipients-100614133","NCT07275632","The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients","A Multicenter, Single-Arm, Exploratory Study Evaluating the Effect of Perioperative Oral Vonoprazan Fumarate on the Incidence of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients","Inclusion Criteria:\n\n* Age ≥ 18 years at time of transplantation.\n* Undergoing first-time deceased-donor kidney transplantation.\n* No administration of proton-competitive acid blockers (P-CABs) in the 1 month prior to transplantation.\n* Consent to receive the standard immunosuppressive therapy post-transplantation.\n* Ability and willingness to provide informed consent and comply with study procedures and follow-up.\n* Complete baseline clinical data available.\n\nExclusion Criteria:\n\n* Receiving a living-donor kidney transplant or multi-organ transplantation.\n* Previous history of any solid organ or cellular transplantation (with the exception of corneal transplants).\n* Intraoperative occurrence of hyperacute rejection or confirmed graft non-function (e.g., renal artery thrombosis).\n* Presence of high risk for primary graft non-function (e.g., severe injury to the transplant renal artery).\n* Severe postoperative intestinal obstruction requiring prolonged fasting or inability to take oral medication in perioperative period.\n* Known history of hypersensitivity to vonoprazan fumarate or any of its excipients.\n* Subjects with severe hepatic impairment (Child-Pugh Class C).\n* Concomitant use of strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin).\n* Current therapy with atazanavir or rilpivirine.\n* Any other condition deemed by the investigator to be inappropriate for study participation (e.g., uncontrolled active infection, severe peptic ulcer, pregnancy or lactation).",{"count":415,"type":21},47,[373,24],"This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant recipients. DGF is a common early complication that significantly impacts graft function and long-term transplant survival. This study aims to explore how Vonoprazan Fumarate, a potassium-competitive acid blocker (P-CAB), can potentially improve macrophage phagocytic function, reduce kidney inflammation, and enhance early kidney function recovery.\n\nPatients aged 18 years and older who are undergoing first-time deceased-donor kidney transplantation will be enrolled. Vonoprazan Fumarate will be administered daily starting on the day of transplantation and continuing for seven days post-surgery. The primary endpoint is DGF incidence, while secondary endpoints include kidney function recovery, serum creatinine reduction, estimated glomerular filtration rate, and safety assessments. Adverse events will be monitored, and the study will also explore potential biomarkers for inflammation and graft function.\n\nThe study is expected to provide insights into a potential new therapeutic strategy to reduce DGF and improve early kidney transplant outcomes, potentially benefiting future kidney transplant patients by offering a safer and more effective perioperative treatment option.",[419,420],"Delayed Graft Function","Kidney Transplantation","2025-12-17",{"date":423,"type":32},"2025-12-23",{"date":425,"type":32},"2025-12-10",{"date":133,"type":21},{"name":38,"class":39},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":434,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":442,"locationsCount":40},"100607200","efficacy-and-safety-of-transcranial-alternating-current-stimulation-tacs-in-adolescents-with-first-episode-depression-who-are-drug-naive-a-randomized-double-blind-controlled-pilot-study-100607200","NCT07185464","Efficacy and Safety of Transcranial Alternating Current Stimulation (tACS) in Adolescents With First-episode Depression Who Are Drug-naive: A Randomized, Double-blind, Controlled Pilot Study","Inclusion Criteria:\n\n1.Age 12-18 years; 2.Subjects met the diagnostic criteria for depression in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) as determined by the Childhood Affective Disorders and Schizophrenia Questionnaire (K-SADS-PL) and were currently in a depressive episode; 3.Children's Depression Rating Scale-Revised (CDRS-R) score ≥ 40 points; 4.Not receiving any antidepressant medication during the current depressive episode.\n\nExclusion Criteria:\n\n1.Other comorbid mental disorders in accordance with DSM-5 except anxiety disorders; 2.Depression with psychotic symptoms; 3.Young Mania Rating Scale (YMRS) \\> 13; 4.History of neurological disease (such as epilepsy, brain trauma, etc.) or serious physical disease (such as thyroid disease, lupus erythematosus, diabetes, lung, liver and kidney damage, major trauma, etc.); 5.Previous treatment with electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), tACS or other neurostimulation treatments; 6.Patients currently receiving anti-epileptic drugs or high-dose benzodiazepines; 7.History of alcohol or drug abuse or dependence; 8.Breastfeeding women or pregnant women; 9.Contraindications to MRI; 10.Currently at high risk of suicide.",{"count":49,"type":21},[51],"To evaluate the efficacy of tACS treatment.To determine whether tACS can accelerate symptom remission, improve clinical response rates, and facilitate the recovery of emotional and cognitive functions through standardized clinical assessments.To evaluate the safety of tACS treatment.To assess adverse events and side effects in both the intervention and control groups, ensuring the safety and tolerability of tACS in adolescent populations.",[27],{"date":439,"type":32},"2025-09-22",{"date":56,"type":21},{"date":173,"type":21},{"name":38,"class":39},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":463,"leadSponsor":465,"locationsCount":4},"100606965","efficacy-and-safety-of-monoclonal-antibody-in-acute-phase-of-neuromyelitis-optica-spectrum-disorder-100606965","NCT07182409","Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder","Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder（MAAP-NMO），A Prospective, Multicenter Cohort Study","Inclusion Criteria:\n\n1. Age at onset ≥18 years, any gender.\n2. Patients meeting the 2015 International Panel for NMO Diagnosis (IPND) criteria for NMOSD and currently in the acute phase, defined as new or significantly worsened neurological deficits lasting \\>24 hours, with onset within \\\u003C14 days, excluding pseudo-relapses caused by fever, infection, or metabolic disturbances. The acute relapse must meet at least one of the following clinical phenotypes: a) Optic neuritis (ON): EDSS visual function score ≥3; b) Transverse myelitis (TM): EDSS pyramidal function score ≥2. NMOSD-related syndromes (e.g., area postrema syndrome, acute brainstem syndrome, acute diencephalic syndrome, cerebral syndrome) may be present as concomitant features but cannot be the sole or primary manifestation.\n3. Serum AQP4-IgG positive by cell-based assay (CBA) with a titer ≥1:32, and negative for MOG-IgG (CBA or LCBA) and GFAP-IgG.\n4. Expanded Disability Status Scale (EDSS) score at enrollment ≥3 and ≤8 points.\n5. Planned to receive or currently receiving intravenous methylprednisolone (IVMP) treatment, and not on or only using conventional immunosuppressive maintenance therapy.\n6. Able to comply with standardized follow-up, with an expected minimum follow-up of 12 months during the study period.\n7. Signed informed consent by the patient or legal guardian (if applicable).\n\nExclusion Criteria:\n\n1. Participation in a randomized clinical trial with blinded treatment allocation.\n2. Received treatment with monoclonal antibody (including rituximab, satralizumab, inebilizumab, eculizumab, efgartigimod, etc.) within 3 months prior to screening.\n3. Received treatment with IVIg, plasma exchange (PE), IVMP, or oral corticosteroids \\>30 mg\u002Fday within 1 month prior to screening.\n4. Incomplete or unavailable follow-up data, expected inability to complete follow-up, or poor compliance.\n5. Patients who have independently discontinued immunotherapy or demonstrate poor adherence.\n6. Presence of severe underlying diseases or other conditions that may affect the safety of immunotherapy or the interpretation of study results, including but not limited to: a) Chronic or active infections requiring long-term systemic treatment (e.g., progressive multifocal leukoencephalopathy, chronic renal infection, chronic respiratory infection with bronchiectasis, active tuberculosis, active hepatitis C, etc.); b) Positive hepatitis B serology (except in individuals with prior vaccination); c) History or suspicion of tuberculosis; d) Positive HIV serology; e) History or current clinically significant adverse reactions (including severe allergic reactions) related to corticosteroids, FcRn antagonists, or complement inhibitors.\n7. Pregnant or breastfeeding women, or women planning pregnancy in the near future (contraception required during treatment).\n8. Any other condition deemed by the investigators to make participation in the study inappropriate.",{"count":225,"type":21},"This study aims to evaluate the efficacy and safety of different monoclonal antibody in the acute phase of neuromyelitis optica spectrum disorder (MAAP-NMO). It will also examine immune-related biomarkers and their relationship with treatment response to provide evidence for optimizing acute-phase therapeutic strategies.",[453],"NMOSD",[453,455,456,457,458],"Intravenous methylprednisolone","Efgartigimod","Eculizumab","Plasma exchange","2025-09-12",{"date":461,"type":32},"2025-09-19",{"date":56,"type":21},{"date":464,"type":21},"2027-06-30",{"name":38,"class":39},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":66,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":474,"briefSummary":475,"conditions":476,"keywords":478,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":486,"locationsCount":4},"100604003","efficacy-and-safety-of-stapokibart-for-primary-cutaneous-amyloidosis-100604003","NCT07143864","Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis","Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis: A Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n1. Males or females aged 18 to 75 years, with a diagnosis of PCA confirmed by skin biopsy, and an IGA score of ≥3, a AASI score of ≥5, and a BSA involvement of ≥5%.\n2. Subjects who have received at least 4 weeks of mid-to-high potency or at least 2 weeks of very high potency topical corticosteroids (TCS) or an adequate course of systemic corticosteroids within the 6 months prior to screening, but with an inadequate response; or subjects who are unable to receive the above treatments due to adverse reactions or potential risks.\n3. Prior to the first dose, subjects must have used a moisturizer continuously for at least 1 week, once daily, and must continue to use it throughout the study period.\n4. Able to understand and complete study-related questionnaires.\n5. Able to read, understand, and are willing to sign the informed consent form.\n6. Willing and able to comply with study visits and related procedures.\n7. Women of childbearing potential must agree to use contraception (such as intrauterine devices, oral contraceptives, or condoms) during the study and for 6 months after the study ends; must have a negative serum pregnancy test within 7 days before the first dose and must not be breastfeeding; male subjects must agree to use contraception during the study and for 6 months after the study ends.\n\nExclusion Criteria:\n\n1. Use of any of the following treatments within 4 weeks prior to randomization: a. Immunosuppressants or immunomodulators, such as systemic corticosteroids, cyclosporine, mycophenolate mofetil, interferon gamma (IFN-γ), azathioprine, methotrexate, and Janus kinase (JAK) inhibitors; b. UV phototherapy; c. Systemic traditional Chinese medicine (TCM) treatment.\n2. Use of topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), TCM, or phosphodiesterase 4 (PDE-4) inhibitors within 2 weeks prior to randomization.\n3. Receipt of anti-IL-4R monoclonal antibodies, anti-IgE monoclonal antibodies, or other biologics within 12 weeks or 5 half-lives (whichever is longer) prior to randomization.\n4. Receipt of live attenuated vaccines within 12 weeks prior to randomization or planned vaccination during the study period.\n5. Use of antihistamines within 1 week prior to randomization (subjects who have been on a stable dose of antihistamines for at least 7 days prior to randomization and plan to continue during the study period may be included).\n6. Receipt of allergen-specific immunotherapy (desensitization therapy) within 6 months prior to randomization.\n7. Presence of any skin comorbidities that may interfere with study assessments, including but not limited to scabies, cutaneous T-cell lymphoma, psoriasis, etc.\n8. Previous receipt of at least 12 consecutive doses of anti-IL-4Rα or IL-13 monoclonal antibodies with inadequate clinical response (defined as failure to achieve AASI 50 during treatment).\n9. Presence of any other significant medical history that the investigator deems would pose a risk to the subject's safety or be poorly controlled if the subject participates in the study, in addition to PCA.\n10. History of known or suspected immunosuppression (immunodeficiency), including a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis), even if the infection has resolved; or unusual frequency, recurrence, or chronicity of infections (at the investigator's discretion).\n11. Subjects with any type of active malignancy or a history of malignancy (except for cervical cancer that has been cured for more than 5 years prior to the screening period, or non-metastatic squamous cell carcinoma of the skin, basal cell carcinoma, and papillary thyroid cancer).\n12. Presence of active Mycobacterium tuberculosis infection.\n13. Subjects with severe liver or kidney function impairment during the screening period, such as aspartate aminotransferase or alanine aminotransferase \\>2 times the upper limit of normal (ULN), total bilirubin \\>1.5 times ULN, serum creatinine \\>1.2 times ULN, etc.\n14. Presence of active hepatitis during the screening period, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for hepatitis C virus (HCV) antibody and HCV-RNA.\n15. Positive for HIV antibody during the screening period, or history of HIV infection.\n16. Positive for Treponema pallidum antibody during the screening period (subjects who have undergone standard treatment and have a negative non-treponemal antigen serological test may participate in the study).\n17. Participation in another clinical trial of a drug or medical device within 12 weeks prior to randomization.\n18. Presence of chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to randomization. After resolution of the infection, the subject may be re-screened once.\n19. Subjects who plan to undergo major surgical procedures during the study period.\n20. Pregnant or breastfeeding women.\n21. Subjects with a history of alcoholism, drug abuse, or known drug dependence.\n22. History of atopic keratoconjunctivitis involving the cornea.\n23. Any medical or psychiatric conditions that the investigator deems would pose a risk to the subject, interfere with participation in the study, or confound the interpretation of study results.",{"count":225,"type":21},[51],"This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.",[477],"Primary Cutaneous Amyloidosis",[479,480],"primary cutaneous amyloidosis","Stapokibart","2025-08-23",{"date":483,"type":32},"2025-08-27",{"date":192,"type":21},{"date":133,"type":21},{"name":38,"class":39},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":16,"minAge":494,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":40},"100595040","noninvasive-intratumor-heterogeneity-evaluation-in-hnscc-100595040","NCT07027280","Noninvasive Intratumor Heterogeneity Evaluation in HNSCC","Noninvasive Intratumor Heterogeneity Evaluation in HNSCC With Multi-omics Insights and Therapeutic Targets","Inclusion Criteria:\n\nPathologically confirmed head and neck squamous cell carcinoma (HNSCC). Complete clinical, imaging, and pathological data. Available complete follow-up information.\n\nExclusion Criteria:\n\nPatients who received chemotherapy or radiotherapy before surgery. Poor image quality. Tumors too small to be easily identified. History of other concurrent malignant tumors.","15 Years","89 Years",{"count":497,"type":21},700,"This study focuses on tumor heterogeneity, a core challenge in the field of oncology, and innovatively utilizes patient imaging data to deeply mine and analyze intratumoral heterogeneity. By constructing an imaging analysis model for tumor heterogeneity and associating this model with clinical, pathological, transcriptomic, and metabolomic data of patients, a multi-omics decoding of tumor heterogeneity is achieved. The main questions it aims to address are:\n\nCan the ITH model stratify patients' treatment efficacy and prognosis assessment? Can pathological and multi-omics sequencing map the mechanisms behind the ITH model?",[500],"Head and Neck Cancer","2025-06-16",{"date":503,"type":32},"2025-06-18",{"date":505,"type":32},"2025-02-27",{"date":507,"type":21},"2025-08-15",{"name":38,"class":39},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":16,"minAge":18,"maxAge":66,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":4},"100594267","immunonutrition-effects-on-nutrition-and-immunity-in-hnc-during-radiotherapy-100594267","NCT07017218","Immunonutrition Effects on Nutrition and Immunity in HNC During Radiotherapy","The Impact of Immune Nutrition on Nutritional and Immune Status of Head and Neck Cancer Patients During Radiotherapy","Inclusion Criteria:\n\n* Patients must be histologically or cytologically confirmed to have head and neck cancer (HNC).\n* Scheduled for radiotherapy with or without concurrent chemotherapy.\n* Willingness to sign informed consent voluntarily.\n* Aged between 18 and 75 years old.\n* Karnofsky Performance Status (KPS) score ≥70.\n* Hematological and biochemical parameters within the following ranges:\n* White blood cell count (WBC) ≥3.5×10\\^9\u002FL\n* Hemoglobin (Hb) ≥90 g\u002FL\n* Platelet count (PLT) ≥100×10\\^9\u002FL\n* Serum albumin (ALB) ≥30 g\u002FL\n* Total bilirubin ≤1.5 times the upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 - times ULN\n* Life expectancy of at least 6 months.\n* No severe malnutrition at baseline (e.g., body mass index \\[BMI\\] \\>18.5 kg\u002Fm²).\n\nExclusion Criteria:\n\n* Prior history of radiation therapy or biological therapy targeting the head and neck region.\n* History of other malignant tumors in the past 5 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ.\n* Severe systemic diseases, such as uncontrolled diabetes mellitus, severe cardiovascular disease, or chronic renal failure.\n* Pregnancy or lactation.\n* Drug or alcohol abuse.\n* Participation in other clinical trials within the last 3 months.\n* Known allergies or contraindications to the nutritional formulations used in this study.\n* Mental disorders or cognitive impairments that may affect compliance with the study protocol.\n* Inability to tolerate oral nutritional supplements (ONS).\n* Any condition deemed by the investigator to potentially interfere with the study objectives or participant safety",{"count":517,"type":21},48,[51],"Head and neck cancer (HNC) is one of the most common types of malignant tumors, often leading to malnutrition due to its complex anatomical location near many functional organs. Radiotherapy, an essential treatment modality for HNC, can exacerbate malnutrition, potentially causing radiotherapy failure. Both domestic and international guidelines advocate early nutritional intervention for HNC patients at risk of malnutrition; however, specific recommendations on the type of nutritional treatment are lacking. Immunonutrition has shown promise in regulating the immune microenvironment, enhancing immune response, and reducing radiotherapy side effects compared to conventional nutritional interventions. However, there is a lack of studies focusing on immunonutritional therapy during the radiotherapy process for HNC in China. Therefore, this study aims to investigate the effects of immunonutrition on nutritional status, immune function, and quality of life (QoL) in head and neck cancer (HNC) patients undergoing radiotherapy.\n\nThis prospective interventional study enrolled 48 head and neck cancer (HNC) patients scheduled to undergo radiotherapy (with or without concurrent chemotherapy). All participants received an immunonutrition formula supplemented with arginine, ω-3 fatty acids, and nucleotides. Throughout the radiotherapy course, certified dietitians and oncology nurses provided standardized nutritional guidance based on a five-step nutritional management protocol. Primary outcomes included:Radiotherapy-related adverse events (e.g., mucositis, dysphagia) assessed at four time points during radiotherapy (weeks 1, 3, 5, and 7) using CTCAE v4.0 criteria;Longitudinal changes in nutritional status (serum albumin, BMI), immune-related biomarkers , and quality of life were assessed at baseline, mid-radiotherapy (week 4), and post-treatment (week 7).",[500,521],"Nutrition",[523,524,525],"Head and neck cancer","immunonutrition","radiation","2025-06-11",{"date":528,"type":32},"2025-06-12",{"date":530,"type":21},"2025-06-20",{"date":532,"type":21},"2026-02-28",{"name":38,"class":39},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":318,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":540,"targetDuration":542,"studyType":69,"phases":4,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":556,"locationsCount":4},"100572936","research-on-the-sources-of-noise-in-post-anesthesia-care-unit-and-the-impact-of-noise-on-medical-staff-100572936","NCT06739746","Research on the Sources of Noise in Post Anesthesia Care Unit and the Impact of Noise on Medical Staff","Inclusion Criteria:\n\n* Currently working as nurses, doctors, or technicians in the Post Anesthesia Care Unit;\n* Have at least continuous 6 months of work experience in the Post Anesthesia Care Unit;\n* Able to read and answer questionnaires in Chinese fluently.\n\nExclusion Criteria:\n\n* Have hearing impairments or other conditions affecting auditory perception;\n* Have participated in similar studies and completed related surveys within the past 6 months.",{"count":541,"type":21},400,"1 Week","The study aims to clarify the sources and influencing factors of noise in the post anesthesia care unit, as well as the perception of noise by medical staff through survey table, in order to improve the noise environment, optimize noise management, protect medical staff, and enhance medical quality.",[545],"Noise Exposure",[547,548,549],"Noise","Post anesthesia care unit","Medical staff","2025-05-29",{"date":552,"type":32},"2025-05-31",{"date":554,"type":21},"2025-06-01",{"date":34,"type":21},{"name":38,"class":39},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":318,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":22,"phases":564,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":576,"locationsCount":40},"100548312","early-phase-1-68gaga-sa-dabi-4-pet-imaging-of-stimulator-of-interferon-gene-expression-in-cancer-patients-100548312","NCT06419361","[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Signed informed consent.\n3. Patients with suspected or newly diagnosed or previously malignant disease.\n\nExclusion Criteria:\n\n1. Patients with non-malignant disease.\n2. Patients with pregnancy.\n3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.\n4. Known or expected hypersensitivity to \\[68Ga\\]Ga-Sa-DABI-4 or any of its components.\n5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.",{"count":49,"type":21},[565],"EARLY_PHASE1","Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\\[68Ga\\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.",[568,569,570],"Stimulator of Interferon Gene","Cancer","Positron Emission Tomography",{"date":572,"type":32},"2025-06-04",{"date":574,"type":32},"2024-05-30",{"date":133,"type":21},{"name":38,"class":39},""]